Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:
Fulgent Genetics Inc (NASDAQ: FLGT)
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent’s product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; Canada; and Other Countries.
A quick look at the price chart below shows us that the stock is down 27% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 1.82, which means that it remains undervalued.
Superinvestors who currently hold positions in the company include:
Ken Griffin – 257,420
Steve Cohen – 223,995
Ray Dalio – 27,770
Joel Greenblatt – 24,875
John Hussman – 15,500
Cliff Asness – 12,082
Israel Englander – 9,538
Chuck Royce – 4,917
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple: